Boston Scientific Announces First Quarter Spe...(to be incorrect or if certain risks or u...)

Date:4/15/2009

to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan                     Larry Neumann
              508-650-8541 (office)            5
'/>"/>
SOURCE  Boston Scientific
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. Boston Scientific Launches New Coronary Imaging Catheter
2. Moodys Raises Boston Scientifics Rating Outlook to Stable
3. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
5. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory
6. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
7. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
8. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
9. Boston Scientific Acquires Labcoat Limited
10. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
11. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference